Autoimmune type 1 diabetes diagnosis
Over 9 million people worldwide are living with autoimmune type 1 diabetes,1 a disease with a progressive nature caused by the loss of insulin-producing cells
How to suspect and diagnose autoimmune type 1 diabetes?
Diagnosis of autoimmune type 1 diabetes usually happens once the disease has progressed into high blood glucose or even a medical emergency when left untreated.
Early detection of autoimmune type 1 diabetes provides a better way to be introduced to living with the condition,4 putting you in the driver’s seat. Screening is a proactive way to detect and manage type 1 diabetes, helping you look after your health at every stage of the journey.4
An early diagnosis of autoimmune type 1 diabetes allows you to learn more about the condition and how to confidently manage it before the onset of symptoms. This knowledge eases worry and distress when autoimmune type 1 diabetes progresses to later, symptomatic stages.4 Discover what happens after screening.
Can autoimmune type 1 diabetes be detected early through screening?
In autoimmune type 1 diabetes, the body's immune cells produce antibodies mistakenly against the insulin-producing cells (beta cells) in the pancreas. These so-called autoantibodies can appear years before the first symptoms emerge.
The detection of autoantibodies through screening allows doctors to identify people who have a higher chance of developing autoimmune type 1 diabetes.2 In particular, individuals with relatives who have autoimmune type 1 diabetes are up to 15 times more likely to develop the condition and are recommended to be screened.4
Calculate your risk of autoimmune type 1 diabetes.
Screening can detect autoimmune type 1 diabetes early, but further tests are needed to firmly diagnose the condition and identify the stage at which people are.5
Learn more about screening in autoimmune type 1 diabetes.
Can autoimmune type 1 diabetes be detected early through screening?
In autoimmune type 1 diabetes, the body's immune cells produce antibodies mistakenly against the pancreas.2 These so-called autoantibodies can appear years before the first symptoms emerge.
The detection of these autoantibodies through screening allows doctors to identify people who have a higher chance of developing autoimmune type 1 diabetes.2 In particular, individuals with a relative with autoimmune type 1 diabetes have an increased likelihood of developing autoimmune type 1 diabetes and are recommended to be screened.1,6
Doctors also use screening for autoantibodies to confirm a suspected type 1 diabetes diagnosis, because high blood glucose levels alone are not enough for a firm type 1 diabetes diagnosis..7
However, screening may not always find autoantibodies - 90% of relatives of people with autoimmune type 1 diabetes will not show any detectable autoantibodies.4
Learn more about screening in T1D.
What are the diagnostic tests for autoimmune type 1 diabetes?
Autoimmune type 1 diabetes can cause a wide range of symptoms, including unexplained weight loss, frequent urination, and increased thirst and tiredness.2,3
These symptoms play an important role in the diagnosis of symptomatic type 1 diabetes patients, however, it’s also now possible to detect autoimmune type 1 diabetes before the onset of symptoms through screening.4
Autoantibody (AAB) screening
Screening for type 1 diabetes autoantibodies is a key test to detect autoimmune type 1 diabetes.5 Autoantibody tests detect autoantibodies that the body mistakenly produces against insulin-producing beta cells in the pancreas.2
In addition to autoantibody testing, other tests are used to determine the stage of autoimmune type 1 diabetes.6 Your doctor might conduct the following tests to determine the stage:
Glycated hemoglobin (HbA1c) test
The HbA1c test determines the average blood glucose levels of the past 3 months. An HbA1c level between 5.7 –6.4% indicates stage 2 autoimmune type 1 diabetes, while a value of or above 6.5% suggests stage 3. People with autoimmune type 1 diabetes will need to get familiar with their A1C level because regular HbA1c assessments are used to monitor the disease and adjust treatment when necessary.6,7
Fasting blood glucose test
This test measures blood glucose levels after at least 8 hours without food and drink except for water. In the case of autoimmune type 1 diabetes, a blood glucose value between 100 –125 mg/dL is usually associated with stage 2, while 126 mg/dL or more in repeated fasting blood glucose tests indicates stage 3.6,8
Oral glucose tolerance test
The oral glucose tolerance test assesses blood glucose before and after a medical glucose drink. In the case of autoimmune type 1 diabetes, a value between 140 –199 mg/dL 2 hours after the drink is consumed points to stage 2, while a value of at least 200 mg/dL suggests stage 3.6,8
Random blood glucose test
This test measures blood glucose at any time of the day. Blood glucose levels are determined at random with this test. In the case of autoimmune type 1 diabetes, values at or above 200 mg/dL indicate stage 3.8
What is the average age for an autoimmune type 1 diabetes diagnosis?
Autoimmune type 1 diabetes can be detected years before a diagnosis is made. Currently, the most common age for an autoimmune type 1 diabetes diagnosis is between 10-14 years old.9 However, it is now widely recognised that adults get it too, with up to 62% of new autoimmune type 1 diabetes cases occurring in adulthood.
Autoimmune type 1 diabetes can affect anyone at any age.10 In most cases, type 1 diabetes autoantibodies show the first peak between 9 months and 2 years.11
To detect autoimmune type 1 diabetes as early as possible, screening for autoimmune type 1 diabetes should therefore be done in young children, ideally at the ages of 2 and 6.12 In addition, individuals with a higher chance of developing type 1 diabetes are recommended to be screened. This group includes people with a family history of type 1 diabetes and those with certain autoimmune diseases.4
How late can autoimmune type 1 diabetes be diagnosed?
Autoimmune type 1 diabetes can be diagnosed at any stage of life. Some people are first diagnosed with autoimmune type 1 diabetes in their 50s and 60s.2,13
Adult patients are often diagnosed at a late stage when symptoms emerge and sometimes become a medical emergency.2,14 Screening for autoimmune type 1 diabetes can help reduce the likelihood of these medical emergencies.14 In particular, people with a family history of autoimmune type 1 diabetes or other autoimmune diseases are recommended to be screened.15 However, the majority of individuals with autoimmune type 1 diabetes do not have a family history of the condition.15
Talk to a healthcare professional about screening if you suspect that you or your loved ones might be at risk of developing autoimmune type 1 diabetes.
Learn more about risk factors for autoimmune type 1 diabetes.
Is misclassification of type 1 diabetes possible?
A misclassification is possible and mostly occurs in adults over 30 years old.5 Autoimmune type 1 diabetes and prediabetes cause similar high blood glucose levels, making it difficult to distinguish the two conditions at this stage.6
Autoimmune type 1 diabetes can also be misdiagnosed as type 2 diabetes, as both conditions cause similar symptoms.13,16 Around 77% of adults with autoimmune type 1 diabetes are initially misdiagnosed with type 2 diabetes.17,18
While it’s easy to confuse them, they are completely different. Prediabetes is a condition that precedes type 2 diabetes and can be reversed by diet and exercise, whereas autoimmune type 1 diabetes cannot be stopped or reversed. This is because, unlike autoimmune type 1 diabetes, prediabetes and type 2 diabetes are not autoimmune conditions
Testing for autoantibodies can distinguish type 1 diabetes from type 2 diabetes8 and reduce the chance of misclassification.4
Uncover other common autoimmune type 1 diabetes myths.
What happens after a new type 1 diabetes diagnosis?
It is normal to feel surprised or scared by a new type 1 diabetes diagnosis and to have a lot of questions. Your healthcare team is there to provide education and resources that will empower you to take control of your health with confidence and support.4
There is currently no cure for autoimmune type 1 diabetes, however, new treatments are constantly being developed, making it easier to manage the condition.4
If screening has detected that you may be in the presymptomatic stages of autoimmune type 1 diabetes, then you and your doctor will keep track of the progression of your condition by monitoring changes in blood glucose levels. No insulin therapy is needed at this stage.5,18 In the early, presymptomatic stages, education and psychological support can help prepare you for the journey ahead.4 There are treatment options that can potentially be used to delay the onset of stage 3 autoimmune type 1 diabetes.4
Learn more about what comes next after screening.
If you’re in the symptomatic, clinical stage of autoimmune type 1 diabetes, current management approaches include taking insulin and regular monitoring of blood sugar.5,19 In addition to insulin therapy, exercise, lifestyle changes, and support services can empower you to confidently manage the disease and your well-being.5
References
1. Type 1 Diabetes Index. Type 1 Diabetes Index. July 11, 2022. Accessed August 4, 2025. https://www.t1dindex.org/
2. Katsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3(1):17016. doi:10.1038/nrdp.2017.16
3. Kahanovitz L, Sluss PM, Russell SJ. Type 1 diabetes - A clinical perspective. Point Care. 2017;16(1):37-40. doi:10.1097/POC.0000000000000125
4. Leichter SB, Felton JL, Rasmussen CG, et al. Establishing screening programs for presymptomatic type 1 diabetes: Practical guidance for diabetes care providers. J Clin Endocrinol Metab. Published online April 2, 2025:dgaf194. doi:10.1210/clinem/dgaf194
5. Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2021;44(11):2589-2625. doi:10.2337/dci21-0043
6. American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: Standards of Medical Care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S17-S38. doi:10.2337/dc22-S002
7. Alzahrani BA, Salamatullah HK, Alsharm FS, et al. The effect of different types of anemia on HbA1c levels in non-diabetics. BMC Endocr Disord. 2023;23(1):24. doi:10.1186/s12902-023-01280-y
8. Lucier J, Mathias PM. Type 1 diabetes. In: StatPearls. StatPearls Publishing; 2024. Accessed December 6, 2024. https://www.ncbi.nlm.nih.gov/books/NBK507713/
9. Gong B, Yang W, Xing Y, Lai Y, Shan Z. Global, regional, and national burden of type 1 diabetes in adolescents and young adults. Pediatr Res. 2025;97(2):568-576. doi:10.1038/s41390-024-03107-5
10. Haller MJ, Bell KJ, Besser REJ, et al. ISPAD clinical practice consensus guidelines 2024: Screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes. Horm Res Paediatr. 2024;97(6):529-545. doi:10.1159/000543035
11. Krischer JP, Lynch KF, Schatz DA, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia. 2015;58(5):980-987. doi:10.1007/s00125-015-3514-y
12. Ghalwash M, Dunne JL, Lundgren M, et al. Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2022;10(8):589-596. doi:10.1016/S2213-8587(22)00141-3
13. Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol. 2018;6(2):122-129. doi:10.1016/S2213-8587(17)30362-5
14. Sims EK, Besser REJ, Dayan C, et al. Screening for type 1 diabetes in the general population: A status report and perspective. Diabetes. 2022;71(4):610-623. doi:10.2337/dbi20-0054
15. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974. doi:10.2337/dc15-1419
16. Leslie RD, Evans-Molina C, Freund-Brown J, et al. Adult-onset type 1 diabetes: Current understanding and challenges. Diabetes Care. 2021;44(11):2449-2456. doi:10.2337/dc21-0770
17. Muñoz C, Floreen A, Garey C, et al. Misdiagnosis and Diabetic ketoacidosis at diagnosis of type 1 diabetes: Patient and caregiver perspectives. Clin Diabetes. 2019;37(3):276-281. doi:10.2337/cd18-0088
18. Phillip M, Achenbach P, Addala A, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia. 2024;67(9):1731-1759. doi:10.1007/s00125-024-06205-5
19. Akil AAS, Yassin E, Al-Maraghi A, Aliyev E, Al-Malki K, Fakhro KA. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. J Transl Med. 2021;19(1):137. doi:10.1186/s12967-021-02778-6
MAT-GLB-2505730-v1.0-10/25